A TITAN step forward: apalutamide for metastatic castration-sensitive prostate cancer

Daniel Hyuck-Min Kwon^{1

2}, Terence Friedlander^{1

2}

Affiliations

¹ Department of Medicine, Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA, USA.
² The Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.

Editorial

Daniel Hyuck-Min Kwon et al. Ann Transl Med. 2019 Dec.

. 2019 Dec;7(Suppl 8):S364.

doi: 10.21037/atm.2019.09.21.

Daniel Hyuck-Min Kwon^{1

2}, Terence Friedlander^{1

2}

¹ Department of Medicine, Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA, USA.
² The Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.

No abstract available

Conflict of interest statement

Conflicts of Interest: T Friedlander participated in an advisory board for Janssen. The other author has no conflicts of interest to declare.

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, Juárez Soto Á, Merseburger AS, Özgüroğlu M, Uemura H, Ye D, Deprince K, Naini V, Li J, Cheng S, Yu MK, Zhang K, Larsen JS, McCarthy S, Chowdhury S; TITAN Investigators. Chi KN, et al. N Engl J Med. 2019 Jul 4;381(1):13-24. doi: 10.1056/NEJMoa1903307. Epub 2019 May 31. N Engl J Med. 2019. PMID: 31150574 Clinical Trial.

1. Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med 2015;373:737-46. 10.1056/NEJMoa1503747 - DOI - PMC - PubMed
1. James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016;387:1163-77. 10.1016/S0140-6736(15)01037-5 - DOI - PMC - PubMed
1. Fizazi K, Tran N, Fein L, et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med 2017;377:352-60. 10.1056/NEJMoa1704174 - DOI - PubMed
1. James ND, de Bono JS, Spears MR, et al. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N Engl J Med 2017;377:338-51. 10.1056/NEJMoa1702900 - DOI - PMC - PubMed
1. Smith MR, Antonarakis ES, Ryan CJ, et al. Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort. Eur Urol 2016;70:963-70. 10.1016/j.eururo.2016.04.023 - DOI - PMC - PubMed